Anixa Biosciences Inc

NASDAQ ANIX

Data sourced from

and

Daily

Download Data

Anixa Biosciences Inc Price to Earnings Ratio (P/E) on June 03, 2024: -17.08

Anixa Biosciences Inc Price to Earnings Ratio (P/E) is -17.08 on June 03, 2024, a -67.63% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Anixa Biosciences Inc 52-week high Price to Earnings Ratio (P/E) is -8.33 on November 08, 2023, which is 51.24% above the current Price to Earnings Ratio (P/E).
Anixa Biosciences Inc 52-week low Price to Earnings Ratio (P/E) is -24.79 on March 20, 2024, which is -45.14% below the current Price to Earnings Ratio (P/E).
Anixa Biosciences Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -13.79.

NASDAQ: ANIX

Anixa Biosciences Inc

CEO	Dr. Amit Kumar Ph.D.
IPO Date	Jan. 1, 1987
Location	United States
Headquarters	3150 Almaden Expressway, San Jose, CA, United States, 95118
Employees	4
Sector	Healthcare
Industry	Biotechnology

Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Key trends